GlassScriptPhysician profile
April L Evans
NPI 1164109740
$2,084.15
in general payments reported to CMS, 2019-2025
30 companies · $657 in 2025
The $657 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $247 · 2024: $1,179 · 2025: $657.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,023 · Education: $60.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,023.40 |
| Education | $60.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $583.46 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $199.13 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $175.64 | 2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $174.05 | 2023-2025 | |
| Corcept Therapeutics | $141.18 | 2024-2025 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $124.80 | 2023-2024 | Xifaxan |
| Abiomed | $97.24 | 2024-2025 | Impella |
| Sumitomo Pharma America, INC. | $81.98 | 2024-2025 | Gemtesa |
| Amgen INC. | $54.63 | 2024-2025 | Evenity, Repatha, Otezla |
| Daiichi Sankyo INC. | $42.49 | 2024-2025 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $39.70 | 2023-2024 | |
| Pfizer INC. | $32.99 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $31.69 | 2024 | Verquvo, Vaxneuvance, Vaxelis |
| Agios Pharmaceuticals, INC. | $29.29 | 2023-2024 | Pyrukynd |
| Otsuka America Pharmaceutical, INC. | $28.30 | 2023-2024 | Rexulti |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recor Medical INC | $25.84 | 2024 | Paradise |
| Esperion Therapeutics, INC. | $24.53 | 2025 | Nexletol |
| Halozyme INC | $18.80 | 2023 | |
| Janssen Pharmaceuticals, INC | $17.91 | 2025 | Spravato |
| Eisai INC. | $17.56 | 2025 | |
| Kyowa Kirin, INC. | $17.25 | 2024 | Crysvita |
| Glaxosmithkline, LLC. | $16.34 | 2024 | Shingrix |
| Axsome Therapeutics, INC. | $15.67 | 2025 | Symbravo |
| Sanofi-Aventis U.S. LLC | $15.08 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.85 | 2025 | Jardiance |
| Idorsia Pharmaceuticals US INC | $14.60 | 2024 | Quviviq |
| Edwards Lifesciences Corporation | $14.39 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Corium, LLC | $14.17 | 2023 | Azstarys |
| Novartis Pharmaceuticals Corporation | $13.55 | 2023 | |
| Organon LLC | $7.04 | 2025 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw April Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.